Skip to main content
Equibles
OCUL logo

OCUL · Ocular Therapeutix, Inc · Webcasts, Transcripts & Audio

Track OCUL — free

Use OCUL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research OCUL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.96 -0.33 (-4.53%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Market Cap
$2.12B
Shares
219.62M
Volume · Oct 2 4.96M Avg daily vol (3M) 2.73M

Ocular Therapeutix, Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Ocular Therapeutix, Inc (OCUL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲79.6% $13.19M −$12.54M '22 Q1 22-05-09 ▲4.7% $12.27M −$18.77M '22 Q2 22-08-08 ▼1.5% $11.96M −$24.19M '22 Q3 22-11-07 ▲14.4% $14.08M −$15.54M '22 Q4 23-01-06 ▲1.4% $13.37M −$30.32M '23 Q1 23-05-08 ▲23.8% $15.19M −$20.68M '23 Q2 23-08-07 ▲26% $15.08M −$516,000 '23 Q3 23-11-07 ▲10.5% $14.77M −$64.85M '24 Q1 24-05-07 ▲8.3% $16.44M −$43.78M '24 Q2 24-08-07 ▲2.3% $15.43M −$36.49M '24 Q3 24-11-14 ▲15.4% $17.08M −$48.39M '24 Q4 25-03-03 ▼18.1% $13.46M −$67.81M '25 Q2 25-08-05 ▼5.7% $14.54M −$69.42M '25 Q3 25-11-04 ▼22.4% $13.25M −$64.65M '25 Q4 26-02-05 ▲0.8% $10.79M −$88.61M '26 Q1 26-05-05 LATEST ▲0.1% $13.47M −$78.76M '26 Q2 26-08-03
Conference
Investor event
2026-10-20
Ocular Therapeutix, Inc (OCUL) October 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-03
Ocular Therapeutix, Inc (OCUL) Q2 2026 Earnings Call
Revenue
$13.47M
▲ 0.1% YoY
Diluted EPS
$-0.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-05
Ocular Therapeutix, Inc (OCUL) Q1 2026 Earnings Call Transcript
Confident tone X-Paxly SOL1 Phase 3 superiority in wet AMD NDA submission and regulatory pathway SOLAR confirmatory trial
Revenue
$10.79M
▲ 0.8% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-05
Ocular Therapeutix, Inc (OCUL) Q4 2025 Earnings Call
Revenue
$13.25M*
▼ 22.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Ocular Therapeutix, Inc (OCUL) Q3 2025 Earnings Call Transcript
Confident tone AXPAXLI superiority label strategy SOL-1 and SOL-R wet AMD registrational trials HELIOS diabetic retinopathy program
Revenue
$14.54M
▼ 5.7% YoY
Diluted EPS
$-0.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Ocular Therapeutix, Inc (OCUL) Q2 2025 Earnings Call Transcript
Confident tone AXPAXLI registrational program / SOL trials Trial quality, retention and rescue conduct Label / patient population exclusions (OCT fluctuations)
Revenue
$13.46M
▼ 18.1% YoY
Diluted EPS
$-0.39
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Ocular Therapeutix, Inc (OCUL) Q4 2024 Earnings Call Transcript
Confident tone AXPAXLI registrational program in wet AMD SOL-R trial optimization and sample size reduction FDA SPA amendment and redosing strategy
Revenue
$17.08M*
▲ 15.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Ocular Therapeutix, Inc (OCUL) Q3 2024 Earnings Call Transcript
Confident tone AXPAXLI Wet AMD SOL-1 and SOL-R Trials Regulatory Pathway / FDA Diabetic Retinopathy / DME Opportunity
Revenue
$15.43M
▲ 2.3% YoY
Diluted EPS
$-0.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Ocular Therapeutix, Inc (OCUL) Q2 2024 Earnings Call Transcript
Confident tone SOL-1 registration study enrollment SOL-R repeat-dosing registration study FDA alignment on study designs
Revenue
$16.44M
▲ 8.3% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Ocular Therapeutix, Inc (OCUL) Q1 2024 Earnings Call
Revenue
$14.77M
▲ 10.5% YoY
Diluted EPS
$-0.49
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q3
2023-11-07
Ocular Therapeutix, Inc (OCUL) Q3 2023 Earnings Call Transcript
Revenue
$15.08M
▲ 26% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Ocular Therapeutix, Inc (OCUL) Q2 2023 Earnings Call Transcript
Revenue
$15.19M
▲ 23.8% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Ocular Therapeutix, Inc (OCUL) Q1 2023 Earnings Call Transcript
Revenue
$13.37M
▲ 1.4% YoY
Diluted EPS
$-0.39
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-06
Ocular Therapeutix, Inc (OCUL) Q4 2022 Earnings Call Transcript
Revenue
$14.08M*
▲ 14.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Ocular Therapeutix, Inc (OCUL) Q3 2022 Earnings Call Transcript
Revenue
$11.96M
▼ 1.5% YoY
Diluted EPS
$-0.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Ocular Therapeutix, Inc (OCUL) Q2 2022 Earnings Call Transcript
Revenue
$12.27M
▲ 4.7% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Ocular Therapeutix, Inc (OCUL) Q1 2022 Earnings Call Transcript
Revenue
$13.19M
▲ 79.6% YoY
Diluted EPS
$-0.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Ocular Therapeutix, Inc (OCUL) Q4 2021 Earnings Call Transcript
Revenue
$12.31M*
▲ 67.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Ocular Therapeutix, Inc (OCUL) Q3 2021 Earnings Call Transcript
Revenue
$12.15M
▲ 106.8% YoY
Diluted EPS
$-0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-22
Ocular Therapeutix, Inc (OCUL) Q2 2021 Earnings Call Transcript
Revenue
$11.72M
▲ 646.8% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Ocular Therapeutix, Inc (OCUL) Q1 2021 Earnings Call Transcript
Revenue
$7.34M
▲ 181.4% YoY
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Ocular Therapeutix, Inc (OCUL) Q4 2020 Earnings Call Transcript
Revenue
$7.35M*
▲ 225.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Ocular Therapeutix, Inc (OCUL) Q3 2020 Earnings Call Transcript
Revenue
$5.88M
▲ 608.8% YoY
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-17
Ocular Therapeutix, Inc (OCUL) Q2 2020 Earnings Call Transcript
Revenue
$1.57M
▲ 141.4% YoY
Diluted EPS
$-0.64
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-08
Ocular Therapeutix, Inc (OCUL) Q1 2020 Earnings Call Transcript
Revenue
$2.61M
▲ 430.3% YoY
Diluted EPS
$-0.41
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–25 of 25 webcasts
Key facts CIK 1393434 CUSIP 67576A100 13F (30d) 7 filings 7 filers Visit website Investor relations